A new multi-million national media campaign has been launched by Irvine, California’s ChromaDex Corporation (OTCBB:CDXC) for its recently commercialized BluScience™ line of dietary supplements.  The help facilitate the media blitz – which will include television, radio and digital outlets - ChromaDex has retained RJ Palmer, a NYC-based full service media agency with billings in excess of $800 million.  RJ Palmer, a subsidiary of holding company, MDC Partners, provides strategic insights, TV, Print, OOH (Out of Home), radio and online media planning and buying as well as corporate barter and branded entertainment.

The radio campaign began in early March, and the television campaign began this week, said ChromaDex in a statement this morning.

The recently launched (began early in 2012) BluScience™ line is currently consists of HeartBlu - Healthy Heart Support; EternalBlu - Anti-aging Support; TrimBlu - Weight Management Support; and Blu2Go - Focus & Energy Melt.  The novel ingredient in BluScience™ is ChromaDex’s proprietary, patent-pending , branded as pTeroPure®, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan.  Pterostilbene is a stilbenoid that is naturally found in blueberries and thought to exhibit anti-cancer, anti-hypercholesterolemia, anti-hypertriglyceridemia properties, as well as fight off and reverse cognitive decline.  One capsule of BluScience™ has the equivalent amount of pterostilbene as contained in more than 500 cartons of blueberries.

These products are now available at GNC stores, Walgreens, online at drugstore.com and at thousands of other drugstores and pharmacies through a distribution agreement with healthcare services industry stalwart McKesson Corporation (NYSE:MCK).  ChromaDex anticipates having its products spread across more than 25,000 retail store by the end of 2012 in addition to major online retailers.

To help fund its new marketing initiatives, on February 10, 2012, ChromaDex closed a common stock sale in which it raised $11.175 million by selling shares at 75 cents each.  There are roughly 91 million shares outstanding.  Shares of CDXC put on a run to kick-off 2012 with the new product launch and rose as high as $1.22 each, but have cooled-off since.  Shares are back down near a support level, closing trading yesterday at 63 cents.

ChromaDex (CDXC) Stock Quote and News:

---

Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.